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ABSTRACT
The spleen plays an important role in re-
moving normal and abnormal cells from 
the blood and in providing an immuno-
logic response to encapsulated bacteria. 
Surgical splenectomy provides effective 
treatment for several pediatric disorders, 
such as congenital and acquired hemolytic 
anemias, abdominal traumas and immu-
nological and metabolic disorders, but it 
is associated with an immediate and life-
long risk of overwhelming infection. An 
alternative to conventional splenectomy is 
partial splenectomy, recommended espe-
cially in children younger than 5 years of 
age. Recommendations for the prevention 
of overwhelming post-total splenectomy 
infection include: Pneumococcal, Haemo-
philus influenzae type B and Meningococ-
cal immunizations, antimicrobial prophy-
laxis and prompt antibiotic treatment of 
acute febrile illness; conversely, there is no 
clear evidence indicating  which preven-
tion measures are to be performed in pa-
tients undergoing partial splenectomy.




It was initially accepted that the spleen 
not only filters blood but is an important 
regulation center for the body’s immune-
metabolic-endocrine network. (1,2) The 
spleen is part of the lymphatic system. It is 
thought to be central in regulating the im-
mune system, but I plays also a metabolic 
role for its involvement in endocrine func-
tion. Immune function (through phago-
cytosis, but also through T cell-mediated 
immunity and B cell-mediated humoral 
immunity) is the most important function 
of the spleen. (3) The spleen is one of the 
centers of activity of the reticulo-endothe-
lial system and can be considered analo-
gous to a large lymph node, as its absence 
leads to a predisposition toward certain in-
fections. (4,5) It is involved in the produc-
tion of opsonins, properdin, and tuftsin, 
which facilitate  bacterial phagocytosis. 
Another function of the spleen is the crea-
tion of red blood cells and lymphocytes 
(extramedullary hematopoiesis). (4) The 
spleen has a reservoir function, consisting 
of 40 ml of blood, one third of produced 
platelets, margined neutrophils, and factor 
VII. It is also involved in the catheresis of 
white blood cells, red blood cells and plate-
lets, old or damaged (culling), and in the 
removal of Howell-Jolly bodies from red 
blood cells (pitting) and parasites. (6)
INDICATIONS FOR SPLENECTOMY
The many indications for splenectomy can 
be divided into medical (hematologic) and 
surgical categories. (7-9) Medical indica-
tions are currently: congenital hemolytic 
anemia, in which red cell abnormalities 
promote splenic hemolysis (hereditary 
spherocytosis (HS), elliptocytosis, pyru-
vate kinase deficiency, sickle cell disease); 
acquired immune disorders, in which red 
cells or platelets are targeted for splenic 
destruction by being coated with autoan-
tibodies (autoimmune thrombocytope-
nia (ITP), chronic autoimmune hemo-
lytic anemia); hypersplenism, in which 
a hypertrophied spleen becomes a red 
cell trap (thalassemia major, congestive 
splenomegaly, splenomegaly from ac-
cumulation, as in Gaucher's disease and 
Niemann-Pick). Surgical indications in-
clude: traumatic rupture; left abdominal 
interventions, intrinsic splenic diseases 
(cysts, primitive tumors). Splenectomy is 
the only rational therapy for symptomatic 
hereditary spherocytosis and hereditary 
elliptocytosis. It is also performed in most 
spleen ruptures and tears. In other cases, it 
must be evaluated on a case-by-case basis. 
The accepted indication for splenectomy 
in thalassemia is an annual demand for 
blood of one and a half times more than in 
patients with splenectomy or a blood con-
sumption of 200 ml/kg/year. Splenectomy 
is indicated in symptomatic chronic ITP 
taking into account that patients with very 
low platelet counts are at risk for a bleed-
ing diathesis leading to subarachnoid, 
intracerebral hemorrhage or other inter-
nal bleeding". Thrombocytopenia should 
last at least be severe (<10.000/mm3) and 
symptomatic.
PROPHYLAXIS POST SPLENECTOMY
All splenectomized patients should receive 
additional vaccinations due to the high 
risk of developing invasive infections by 
encapsulated bacteria (table 1). In elec-
tive splenectomy, vaccinations should be 
carried out at least 2 weeks before the pro-
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cedure and are more effective in children 
over 2 years of age. Vaccinations can be 
administered even after the intervention, 
in case of emergency splenectomy, prob-
ably with lower efficacy. (10) The pneumo-
coccal vaccine protects against the most 
common strains. The anti- Haemophilus 
influenzae type B vaccination is certainly 
indicated in patients at risk, even if no data 
is available with respect to persistence of 
immunity. The anti-meningococcal vac-
cine is poorly immunogenic and confers 
immunity of short duration because the 
rate of vaccine-induced antibodies tends 
to drop significantly after 2-3 years of vac-
cination. Its administration in asplenic 
children is therefore not routinely recom-
mended; it can be prescribed for journeys 
to Nepal, India and Sub-Saharan Africa. 
Since vaccination does not allow complete 
coverage against pathogens in asplenic 
subjects, antibiotic prophylaxis is recom-
mende. In certain patients this may be 
necessary throughout their life, or at least 
for the first two years after surgery. Despite 
prophylaxis, infections are possible from 
resistant strains; hence, in the case of fever 
or signs of severe infection, drug therapy 
is commenced "empirically", targeted to-
wards  pathogens suspected to be the cause 
of the episode. Other preventive measures 
include: avoiding malarial areas, avoiding 
dog bites, and prevention of thrombotic 
risk with an antiplatelet agent, if platelet 
levels are very high (greater than 1000000 
platelets / mm3). (11-13)
DISCUSSION
Because of the risk of post-splenectomy 
sepsis, subtotal (or partial) splenectomy 
has been advocated as an alternative pro-
cedure. (14) The spleen plays a vital role 
in the host defense against infection as a 
component of the reticuloendothelial sys-
tem. (15,16) At birth, the infant has circu-
lating antibodies due to trans-placentally 
acquired IgG from the mother. These IgG 
antibodies disappear during the first 6 
months of life, and for the next 2 years 
most infants lack circulating antibodies. 
This reflects the period of greatest risk of 
contracting invasive infections by encap-
sulated bacteria. In children younger than 
5 years of age, the risk of serious infection 
is 10% versus a 1-2% risk in adults. Two 
thirds of infections occur within 2-3 years 
after splenectomy. A third occurs within 
5 years, but there have also been cases of 
fulminant infections even after 20 years. 
Several authors recommend performing 
a partial splenectomy in children under 5 
years of age, as a major preventive measure 
against overwhelming post-splenectomy 
infection (OPSI), and subsequently a total 
splenectomy, if necessary. (17,18)
Van Wyck et al., have reported that preser-
vation of a splenic remnant, approximately 
one-third the size of the normal spleen, 
seems critical to maintaining this protec-
tive effect in the rat. (19-21) Several authors 
have confirmed the effectiveness of partial 
splenectomy in the treatment of children 
with mild to moderate HS, reserving total 
splenectomy for severe disease. (14)
Partial splenectomy is a viable option for 
selected patients with HS leading to im-
provement in hematologic and clinical 
abnormalities. Although a variable rate of 
regrowth following partial splenectomy 
has been described, it is not necessar-
ily correlated with recurrent hemolysis. 
So partial splenectomy can be performed 
in these patients, with minimal morbidity 
and good results. (22-24) In Shilling et al., 
splenectomy is not suggested in patients 
with mild or moderate anemia. (25)
Partial splenectomy, with preservation of 
around 25% of the normal spleen volume, 
is a safe and effective procedure for retain-
ing immune competence in patients with 
thalassemia and it should be considered a 
major preventive measure against OPSI, 
especially when access to Pneumococcal 
immunizations (effective and mandatory 
measure against OPSI), or compliance with 
continuous oral antibiotics is not optimal.
Splenic regeneration after partial resec-
tion or implantation is much more limited 
and eutopic remnants provide protection 
against blood born pneumococcal chal-
lenges, relative to the remnant size (19); 
Marques et al. suggest that the autotrans-
planted spleen does not sequester dam-
aged red blood cells in the same manner 
as the regenerated spleen after partial 
resection. (26) This is because in the au-
totransplanted spleen there is a reduction 
in white pulp, which is the principal loca-
tion of the fixed macrophages and the site 
of phagocytosis of pneumococci within the 
spleen. Therefore, preservation of a splenic 
remnant with an intact blood supply re-
mains preferable to autotransplantation 
as a means to conserve functional splenic 
function.
The approach to the management (pre-
vention and treatment) of infectious com-
plications is currently very empirical and 
generally based on studies carried out in 
patients with sickle cell disease or single 
case reports. This has often led not only 
to contrasting practices, but also misun-
derstandings from a clinical point of view, 
because decisions are often based on per-
sonal feelings and not on objective scien-
tific data.
Despite several authors agreeing on the 
increased effectiveness of partial splenec-
tomy in preserving the immune function 
of the spleen, especially in children under 
5 years of age, there is no clear evidence to 
support this at the present time. For this 
reason, some authors recommend im-
munization against S. Pneumoniae, Hae-
mophilus Influenzae, and in certain cases 
Neisseria Meningitidis before partial sple-
nectomy, followed by antibiotic prophy-
laxis (penicillin) for 1 year after the proce-
dure. (14,27)
Table 1. Guidelines on the prophylaxis of splenectomized patients (from AIEOP guidelines) 
Prophylaxis by vaccination Antibiotic oral prophylaxis Parenteral antibiotic prophylaxis Empirical fever therapy
Anti-streptococcus pneumoniae 
(PPSV23 E PCV7)
Penicillin V 125 mg twice daily 
(<3 or 5 years)
Penicillin G benzathine 600.000 U 
every 3-4 weeks i.m. 
(weight < 27 kg)
Amoxicillin-Clavulanic acid 25 
mg/kg twice daily 
(max 1 g three times daily)
Anti-Hemophilus 
(PRP-T; PRP-D; HbOC; 
PRP-OMP)
Penicillin V 250 mg twice daily 
(3 or 5 -14 years)
Penicillin G benzathine 1.200.000 
U every 3-4 weeks i.m. 
(weight > 27 kg)
Ceftriaxone 80 mg/kg i.v. once 
daily (max 2 g)
Anti-Neisseria meningitidis 
(tetravalent)
Penicillin V 250/500 mg twice 
daily (adults)
Vancomycin 30 mg/kg/day i.v. in 4 
doses (max 2 g per day) for resist-
ant penicillin pneumococcus
AIEOP, Associazione Italiana Ematologia ed Oncologia Pediatrica.
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